Syneos Health Expands DCT Capabilities


Syneos Health has expanded its Decentralized Clinical Trial capabilities to include a dedicated Decentralized Clinical Trials Site Advocacy Group. The Group will engage with sites and community stakeholders including patients, advocacy groups, industry, academic centers and sponsors, securing valuable insights across the clinical to commercial spectrum—from the mobile research nursing solutions provided by Illingworth Research Group—aiming to better inform decentralized protocol design, data capture and patient retention strategies. The Group will pressure-test, problem-solve and co-create innovative decentralized clinical trial methodologies.

This collaboration expands the existing Syneos Health Scientific and Protocol Optimization Site Advocacy Group program, introduced in 2015.

For more information, click here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
© 2023 MJH Life Sciences

All rights reserved.